{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"CONTINUATION OF ICI TREATMENT:\n\nPatients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity.\n\nPembrolizumab: Given IV\n\nNivolumab: Given IV\n\nAtezolizumab: Given IV\n\nDurvalumab: Given IV\n\nAvelumab: Given IV","id":"EG000","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"title":"Arm A (Immune Checkpoint Inhibitor)"},{"deathsNumAffected":0,"deathsNumAtRisk":2,"description":"DISCONTINUATION OF ICI TREATMENT:\n\nPatients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion.\n\nPembrolizumab: Given IV\n\nNivolumab: Given IV\n\nAtezolizumab: Given IV\n\nDurvalumab: Given IV\n\nAvelumab: Given IV","id":"EG001","otherNumAffected":1,"otherNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"title":"Arm B (Immune Checkpoint Inhibitor)"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Fatigue"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Rotator cuff injury"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":4},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Rash maculo-papular"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Laryngeal inflammation"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Papulopustular rash"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Hyperkeratosis"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Diarrhea"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Fever"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":2},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Myalgia"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Neoplasms benign, malignant and unspecified - other"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Pain in extremity"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Flu like symptoms"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":2,"numEvents":0}],"term":"Skin and subcutaneous tissue disorders - Other"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE 5.0","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":2,"numEvents":1}],"term":"Blurred vision"}],"timeFrame":"2.5 years"}